BDXHealthcare · Medical Instruments & SuppliesThe 14 Wall Street analysts covering Becton, Dickinson & Co. hold a median 12-month price target of $198 — +9.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Becton, Dickinson & Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (98): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (41): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (5): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BDX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +9.5% from it.
Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Aug 2026 | B of A Securities | Maintains | Neutral | $185 → $200 |
| 13 Aug 2026 | RBC Capital | Maintains | Sector Perform | $180 → $190 |
| 13 Aug 2026 | RBC Capital | Maintains | Sector Perform | — |
| 7 Aug 2026 | Citigroup | Maintains | Buy | $198 → $204 |
| 7 Aug 2026 | Citigroup | Maintains | Buy | — |
| 7 Aug 2026 | Piper Sandler | Maintains | Neutral | $161 → $175 |
| 7 Aug 2026 | Piper Sandler | Maintains | Neutral | — |
| 7 Aug 2026 | RBC Capital | Maintains | Sector Perform | $175 → $180 |
| 7 Aug 2026 | RBC Capital | Maintains | Sector Perform | — |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $161 → $170 |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 5 Aug 2026 | TD Cowen | Maintains | Hold | — |
| 5 Aug 2026 | TD Cowen | Maintains | Hold | $163 → $182 |
| 28 July 2026 | UBS | Initiates | Buy | — |
| 28 July 2026 | UBS | Initiates | Buy | $190 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $190 → $180 |
| 11 May 2026 | Barclays | Maintains | Overweight | — |
| 8 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 4 May 2026 | TD Cowen | Maintains | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BDX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 6 Oct 2026, Becton, Dickinson & Co. returned +22.6% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 18% of US stocks
Cheaper than 50% of US stocks
Cheaper than 45% of US stocks
Cheaper than 36% of US stocks
Higher than 40% of US stocks
Higher than 15% of US stocks
Higher than 58% of US stocks
Higher than 73% of US stocks
Higher than 58% of US stocks
Higher than 56% of US stocks
Higher than 73% of US stocks
Higher than 81% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Becton, Dickinson & Co. has a market value of $48.2B and an enterprise value of $64.3B.
Revenue in the twelve months to 30 June 2026: $20.8B. The latest quarter grew 5.4% year on year.
Net income over the same four quarters: $941.0M, a 4.5% net margin.
Free cash flow in the twelve months to 30 June 2026: $2.5B, after $728.0M of capital spending.
Becton, Dickinson & Co. spent $1.2B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 41.1×; forward P/E: 13.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.38%, paying out 72% of earnings.
Becton, Dickinson & Co. employs 72,000 people — $289K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Becton, Dickinson & Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Becton, Dickinson announced a partnership with the U.S. government to expand domestic medical manufacturing, with the headline citing a $19 billion commitment.
Why it matters — The partnership and manufacturing expansion are relevant to BDX watchers because they concern the company’s domestic production of medical products.
BD marked 65 years of manufacturing in Canaan, Connecticut. The company highlighted generations of local employees’ role in maintaining the supply of its BD Syringe.
Why it matters — The anniversary underscores BD’s longstanding manufacturing presence and the Canaan team’s contribution to supplying a medical device used in patient care.
BD announced that Ferass Abuzaina has been named worldwide president of its Surgery business unit, effective immediately.
Why it matters — The appointment is a leadership change in BD’s Surgery business unit that BDX watchers may want to track.
Becton Dickinson plans to invest $19 billion in the US over several years, including $3 billion to expand domestic manufacturing. The investment is part of an agreement with the government to strengthen the supply of essential medical products.
Why it matters — The plan could affect BDX’s domestic manufacturing capacity and role in supplying essential medical products.
BD announced a partnership with the U.S. Government to expand domestic manufacturing and strengthen supply-chain resilience for essential medical consumables. The company said the agreement supports significant U.S. manufacturing investment and increased domestic production.
Why it matters — The partnership concerns the domestic production of essential medical consumables used in approximately 90% of U.S. hospital visits.
The 14 Wall Street analysts covering Becton, Dickinson & Co. have a median 12-month price target of $198, with estimates ranging from $170 to $225. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Becton, Dickinson & Co., 7 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Becton, Dickinson & Co. 93 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Becton, Dickinson & Co. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (98 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +9.5% from the last close, and Ticker Nerd's factor model ranks Becton, Dickinson & Co. 93 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Becton, Dickinson & Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $170 to $225 over the next 12 months.
Becton, Dickinson & Co. returned +22.6% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells a broad range of products used across healthcare and life sciences. Becton, Dickinson and Company serves hospitals, physicians, clinical laboratories, researchers, and public health organizations with medical supplies, diagnostic systems, laboratory equipment, and interventional devices.
The most recent item we track (Benzinga, 6 Oct 2026): "Becton Dickinson Commits Massive $19 Billion To Expand Domestic Medical Manufacturing". Becton, Dickinson announced a partnership with the U.S. government to expand domestic medical manufacturing, with the headline citing a $19 billion commitment.
Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells a broad range of products used across healthcare and life sciences. Becton, Dickinson and Company serves hospitals, physicians, clinical laboratories, researchers, and public health organizations with medical supplies, diagnostic systems, laboratory equipment, and interventional devices. Its current business centers on medical essentials, connected care, biopharma systems, and interventional products, supporting workflows such as specimen handling, medication delivery, infection prevention, vascular access, and surgical procedures. The company’s portfolio also includes tools and technologies used in drug delivery, patient safety, and clinical research. Headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company plays an important role in enabling medical discovery, improving care delivery, and supporting routine operations in healthcare settings worldwide.
CEO Mr. Thomas E. Polen Jr. · 72,000 employees · United States · https://www.bd.com
